Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
The Singaporean company has filed for a Hong Kong IPO, hoping to wow investors with its product that can screen for gastric cancer using blood tests Key Takeaways: Mirex’s blood-based…
RELATED ARTICLES
-
Kindstar Globalgene finds bargain in solid tumor testing acquisition
9960.HK -
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
- Cash-strapped Qiniu charges to market to seize on Hong Kong rally
-
New Horizon Health launches probe into disputed sales figures
6606.HK
- TransThera seeks Hong Kong IPO to sustain cancer drug research
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
- Saimo Tech revs up for another IPO race after two false starts
